Drugged driving arrests in Norway before and after the implementation of per se law

Forensic Science International

Volumn 245, Issue , 2014, Pages 171-177

  Vindenes, Vigdis ^a   Boix, Fernando ^a   Koksæter, Paul ^a   Strand, Maren Cecilie ^a   Bachs, Liliana ^a   Mørland, Jørg ^a   Gjerde, Hallvard ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Driving under the influence; Drugs; Impairment; Legal limits; Per se law

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPRAZOLAM; AMPHETAMINE; BROMAZEPAM; BUPRENORPHINE; CARISOPRODOL; CLONAZEPAM; COCAINE; CODEINE; DIAZEPAM; ETHYLMORPHINE; FENTANYL; FLUNITRAZEPAM; KETAMINE; MEPROBAMATE; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; MIDAZOLAM; MORPHINE; NITRAZEPAM; NORDAZEPAM; OXAZEPAM; OXYCODONE; PHENAZEPAM; PREGABALIN; TRAMADOL; ZOLPIDEM; ZOPICLONE; ALCOHOL BLOOD LEVEL; CENTRAL NERVOUS SYSTEM AGENTS; NARCOTIC AGENT;

ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; CAR DRIVER; CAR DRIVING; CONCENTRATION (PARAMETERS); DRIVING ABILITY; DRIVING UNDER THE INFLUENCE OF DRUG; DRUG ABUSE; DRUG USE; DRUGGED DRIVER; EXPERT WITNESS; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; NORWAY; SAFETY; BLOOD; DRUNKEN DRIVING; LEGISLATION AND JURISPRUDENCE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS;

BLOOD ALCOHOL CONTENT; CENTRAL NERVOUS SYSTEM AGENTS; DRIVING UNDER THE INFLUENCE; HUMANS; NARCOTICS; NORWAY; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 84912002584     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2014.10.038     Document Type: Article

References (43)

1. Blomberg R.D., Peck R.C., Moskowitz H., Burns M., Fiorentino D. The Long Beach/Fort Lauderdale relative risk study. J. Saf. Res. 2009, 40:285-292.
2. Borkenstein R.F., Crowther R.F., Shumate R.F., Ziel W.B., Zylman R. The role of the drinking driver in traffic accidents (the Grand Rapids Study). Blutalkohol Alcohol Drugs Behav. 1974, 11:1-131.
3. Mura P., Kintz P., Ludes B., Gaulier J.M., Marquet P., Martin-Dupont S., et al. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative study. Forensic Sci. Int. 2003, 133:79-85.
4. Laumon B., Gadegbeku B., Martin J.L., Biecheler M.B. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ 2005, 331:1371.
5. Movig K.L., Mathijssen M.P., Nagel P.H., van Egmond T., de Gier J.J., Leufkens H.G., et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid. Anal. Prev. 2004, 36:631-636.
6. Drummer O.H., Gerostamoulos J., Batziris H., Chu M., Caplehorn J., Robertson M.D., et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid. Anal. Prev. 2004, 36:239-248.
7. Mørland J. Drugs and driving in Norway, and example of best practice 2004, 145-153. Council of Europe Publishing.
8. Bjørneboe A., Bjørneboe G.E., Gjerde H., Bugge A., Drevon C.A., Mørland J. A retrospective study of drugged driving in Norway. Forensic Sci. Int. 1987, 33:243-251.
9. Christophersen A.S., Gjerde H., Bjørneboe A., Sakshaug J., Mørland J. Screening for drug use among Norwegian drivers suspected of driving under influence of alcohol or drugs. Forensic Sci. Int. 1990, 45:5-14.
10. Gjerde H., Beylich K.M., Mørland J. Incidence of alcohol and drugs in fatally injured car drivers in Norway. Accid. Anal. Prev. 1993, 25:479-483.
11. Christophersen A.S., Mørland J. Drugged driving, a review based on the experience in Norway. Drug Alcohol Depend. 1997, 47:125-135.
12. Steentoft A., Simonsen K.W., Linnet K. The frequency of drugs among Danish drivers before and after the introduction of fixed concentration limits. Traffic Inj. Prev. 2010, 11:329-333.
13. Jones A.W. Driving under the influence of drugs in Sweden with zero concentration limits in blood for controlled substances. Traffic Inj. Prev. 2005, 6:317-322.
14. Edland-Gryt M. Rusmidler i Norge 2012 (Alcohol and Drugs in Norway) 2012, Norwegian Institute for Alcohol and Drug Research, Oslo.
15. Gjerde H., Christophersen A.S., Normann P.T., Assum T., Øiestad E.L., Mørland J. Norwegian roadside survey of alcohol and drug use by drivers (2008-2009). Traffic Inj. Prev. 2013, 14:443-452.
16. Houwing S., Hagenzieker M., Mathijssen R., Bernhoft I.M., Hels T., Janstrup K., et al. Prevalence of Alcohol and Other Psychoactive Substance in Drivers in General Traffic. Part I: General Results. DRUID Deliverable D 2.2.3 2011, SWOV Institute for Road Safety Research, Leidschendam.
17. Vindenes V., Jordbru D., Knapskog A.B., Kvan E., Mathisrud G., Slørdal L. Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway. Forensic Sci. Int. 2012, 219:1-11.
18. Kristoffersen L., Skuterud B., Larssen B.R., Skurtveit S., Smith-Kielland A. Fast quantification of ethanol in whole blood specimens by the enzymatic alcohol dehydrogenase method. Optimization by experimental design. J. Anal. Toxicol. 2005, 29:66-70.
19. Kristoffersen L., Stormyhr L.E., Smith-Kielland A. Headspace gas chromatographic determination of ethanol: the use of factorial design to study effects of blood storage and headspace conditions on ethanol stability and acetaldehyde formation in whole blood and plasma. Forensic Sci. Int. 2006, 161:151-157.
20. Øiestad E.L., Johansen U., Øiestad Å.M.L., Christophersen A.S. Drug screening of whole blood by ultra-performance liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 2011, 35:280-293.
21. Christophersen A.S. Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J. Anal. Toxicol. 1986, 10:129-131.
22. Gjerde H., Hasvold I., Pettersen G., Christophersen A.S. Determination of amphetamine and methamphetamine in blood by derivatization with perfluorooctanoyl chloride and gas chromatography/mass spectrometry. J. Anal. Toxicol. 1993, 17:65-68.
23. Sauve E.N., Langodegard M., Ekeberg D., Oiestad A.M. Determination of benzodiazepines in ante-mortem and post-mortem whole blood by solid-supported liquid-liquid extraction and UPLC-MS/MS. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2012, 883-884:177-188.
24. Karinen R., Andersen J.M., Ripel A., Hasvold I., Hopen A.B., Morland J., et al. Determination of heroin and its main metabolites in small sample volumes of whole blood and brain tissue by reversed-phase liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 2009, 33:345-350.
25. Berg T., Lundanes E., Christophersen A.S., Strand D.H. Determination of opiates and cocaine in urine by high pH mobile phase reversed phase UPLC-MS/MS. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2009, 877:421-432.
26. Dahl S.R., Olsen K.M., Strand D.H. Determination of gamma-hydroxybutyrate (GHB), beta-hydroxybutyrate (BHB), pregabalin, 1,4-butane-diol (1,4BD) and gamma-butyrolactone (GBL) in whole blood and urine samples by UPLC-MSMS. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2012, 885-886:37-42.
27. Berg T., Jorgenrud B., Strand D.H. Determination of buprenorphine, fentanyl and LSD in whole blood by UPLC-MS-MS. J. Anal. Toxicol. 2013, 37:159-165.
28. Gjerde H., Øiestad E.L., Øiestad Å.M.L., Langødegård M., Gustavsen I., Hjelmeland K. Comparison of zopiclone concentrations in oral fluid sampled with Intercept® Oral Specimen Collection Device, Statsure Saliva Sampler™ and concentrations in blood. J. Anal. Toxicol. 2010, 34:590-593.
29. Kristoffersen L., Strand D.H., Liane V.H., Tvete I.F., Aldrin M. Determination of safety margins for measuring the concentration of 20 drugs in whole blood. Abstracts of the 51st Annual Meeting of the International Association of Forensic Toxicologists, TIAFT 2013.
30. Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab. Rev. 2000, 32:15-44.
31. Schepers R.J., Oyler J.M., Joseph R.E., Cone E.J., Moolchan E.T., Huestis M.A. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin. Chem. 2003, 49:121-132.
32. Huestis M.A., Cone E.J. Methamphetamine disposition in oral fluid, plasma, and urine. Ann. N.Y. Acad. Sci. 2007, 1098:104-121.
33. Ojaniemi K.K., Lintonen T.P., Impinen A.O., Lillsunde P.M., Ostamo A.I. Trends in driving under the influence of drugs: a register-based study of DUID suspects during 1977-2007. Accid. Anal. Prev. 2009, 41:191-196.
34. Fattore L., Fratta W., Beyond T.H.C. The new generation of cannabinoid designer drugs. Front Behav. Neurosci. 2011, 5:60.
35. Nelson M.E., Bryant S.M., Aks S.E. Emerging drugs of abuse. Emerg. Med. Clin. North Am. 2014, 32:1-28.
36. Bretteville-Jensen A.L., Tuv S.S., Bilgrei O.R., Fjeld B., Bachs L. Synthetic cannabinoids and cathinones: prevalence and markets. Forensic Sci. Rev. 2013, 25:7-26.
37. Reisfield G.M., Goldberger B.A., Gold M.S., DuPont R.L. The mirage of impairing drug concentration thresholds: a rationale for zero tolerance per se driving under the influence of drugs laws. J. Anal. Toxicol. 2012, 36:353-356.
38. DuPont R.L., Voas R.B., Walsh J.M., Shea C., Talpins S.K., Neil M.M. The need for drugged driving per se laws: a commentary. Traffic Inj Prev. 2012, 13:31-42.
39. Pedersen A.J., Dalsgaard P.W., Rode A.J., Rasmussen B.S., Muller I.B., Johansen S.S., et al. Screening for illicit and medicinal drugs in whole blood using fully automated SPE and ultra-high-performance liquid chromatography with TOF-MS with data-independent acquisition. J. Sep. Sci. 2013, 36:2081-2089.
40. Homel J. Policing and Punishing the Drinking Driver. A Study of Specific and General Deterrence 1988, New York, NY, Springer Verlag.
41. Andenæs J. Punishment and Deterrence 1974, University of Michigan Press, Ann Arbor, MI.
42. Davey J.D., Freeman J.E. Improving Road safety through deterrence-based initiatives: a review of research. Sultan Qaboos Univ. Med. J. 2011, 11:29-37.
43. Assum T. Reduction of the blood alcohol concentration limit in Norway-effects on knowledge, behavior and accidents. Accid. Anal. Prev. 2010, 42:1523-1530.